Tuesday, November 30, 2021

NEWS

Cuba to ramp up Jusvinza anti-Covid-19 drug production

Cuba to ramp up Jusvinza anti-Covid-19 drug production

Havana, Oct 4 (Prensa Latina) The Center for Genetic Engineering and Biotechnology (CIGB) on Sunday highlighted that new Jusvinza drug is Cuba's first therapeutic product based on synthetic peptide, so its production is expected to ramp up.
Share on facebook
Share on twitter
Share on whatsapp
Share on telegram
Share on email

On Twitter, CIGB´s Head of the synthetic peptide production plant Ever Pérez explained that the Jusvinza production for being handed over to Cuba´s Public Health system is exceeded every quarter of the year.

‘We have produced a great number of important Jusvinza doses, but we intend to increase production levels for coming quarter and next year, maintaining excellence in Jusvinza manufacture,’ Pérez tweeted.

Jusvinza –awarded for technological innovation- is used in Cuba for treating serious and critical Covid-19 patients.

Designed by CIGB, this peptide improves in ventilatory parameters and inflammation markers, which leads to the recovery of Covid-19 people, reaching a recovery rate over 85% of Covid-19 patients in ICUs.

This molecule in its early stages was designed for treating different diseases such as rheumatoid arthritis, but due to its abilities to reduce hyperinflammation caused by coronavirus in serious and critical patients and avoid complications in high-risk patients, its use to fight coronavirus was authorized.

Jusvinza could be used to treat rheumatoid arthritis, juvenile idiopathic arthritis, which affects children and sepsis, specifically in community pneumonia.

pgh/Pll/mgt / joe

RELATED
ÚLTIMO MINUTO
name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.